Eli Lilly Announces Positive Phase 3 Results for Jaypirca Combination

Eli Lilly announced positive Phase 3 clinical trial results for its drug Jaypirca in combination therapy for patients with relapsed CLL/SLL, a type of leukemia and lymphoma. The company stated that the results support the drug's efficacy and safety. The Phase 3 study showed that Jaypirca, when used in combination with another treatment, provided significant improvement in patients. Eli Lilly indicated that these data could accelerate the drug's approval process and offer a new treatment option for patients. The company announced that detailed results will be presented at an upcoming medical conference and shared with regulatory authorities. Eli Lilly noted that while continuing to evaluate Jaypirca's potential, research is ongoing in other cancer types. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 70%

The news indicates that Eli Lilly has received positive Phase 3 results for a key drug candidate, serving as a positive catalyst for the stock. Technical indicators also support this view: although the RSI at 79 is approaching overbought territory, the MACD line remains above the signal line, and upward momentum continues. The price is trading well above the 20- and 50-day moving averages, with a strong 8.8% increase in the last 24 hours. However, due to the overbought level and the risk of short-term profit-taking, the upside may be limited.

RSI 14

79.2

MACD

25.37

24h Δ

8.81%

Canlı Grafikler